A. SARI, M. ERMETE, F. DAĞ, A. ÇALLI, A. BÖLÜKBAŞI, C. GİRGİN

Evaluation of angiogenesis in urothelial carcinoma of bladder and its relation with prognostic factors

Bu çalısmada mesane ürotelyal karsinomlarında anjiogenez ile bilinen prognostik faktörler arasındaki iliskiyi arastırmayı amaçladık. Gereç ve Yöntem: 51 radikal sistektomi materyalinde (yedi pTa, sekiz pT1, onbir pT2, 17 pT3 ve sekiz pT4) klinikopatolojik parametrelerden yas, cinsiyet, patolojik evre, lenf nodu metastazı, lenfatik/vasküler invazyon, perinöral invazyon ve karsinoma in situ varlığına bakıldı. Anjiogenezi değerlendirmek amacıyla immunohistokimyasal olarak CD34 boyası ile damarlar belirlendi. Vasküler alan yoğunluğu (VSD) ve stromada milimetre kare basına düsen damar sayısı (NVES) analiz edildi. Bulgular: Sonuç olarak anjiogenez ile karsinoma in situ haricindeki hiçbir prognostik belirleyici arasında iliski bulunmadı.

Anahtar Kelimeler:

Neoplazm evrelendirilmesi, Antijenler, CD34, İmmünohistokimya, İn situ karsinom, Seyir, Neovaskülarizasyon, fizyolojik, Karsinom, geçiş hücreli, Mesane neoplazmları, Cinsiyet dağılımı, Yaş dağılımı, Lenfatik metastaz

Mesane ürotelyal karsinomlarında anjiogenezin değerlendirilmesi ve prognostik faktörlerle iliskisi

The aim of this study was to evaluate the relationship between the established prognostic indicators and angiogenesis in urothelial carcinoma of the bladder. Materials and Methods: Archival samples from a total of 51 radical cystectomy specimens (seven pTa, eight pT1, eleven pT2, seventeen pT3 and eight pT4) were analysed. For each case clinicopathologic parameters such as, age, sex, grade, pathologic stage, lymph node metastasis, vascular/lymphatic invasion, perineural invasion and the presence of carcinoma-insitu were detected. To evaluate angiogenesis, vessels were immunohistochemically highlighted using CD34 antibody. Vascular surface density (VSD) and number of vessels per square millimetre of stroma (NVES) values were analysed. Results: As a result no relation between angiogenesis and the prognostic factors studied other than the presence of carcinoma in situ could be established.

Keywords:

Neoplasm Staging, Antigens, CD34, Immunohistochemistry, Carcinoma in Situ, Prognosis, Neovascularization, Physiologic, Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Sex Distribution, Age Distribution, Lymphatic Metastasis,

PDF

___

1. Stein JP, Grossfeld GD, Ginsberg DA, et al. Prognostic markers in bladder cancer: a contemporary review of the literature. J Urol. 1998 Sep; 160 (3 Pt 1): 645 - 59.
2. Jaeger TM, Weidner N, Chew K, et al. Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer. J Urol. 1995 Jul; 154 (1): 69 - 71.
3. Bochner BH, Cote RJ, Weidner N, et al. Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst. 1995 Nov 1; 87 (21) :1603 - 12.
4. Streeter EH, Harris AL. Angiogenesis in bladder cancer-prognostic marker and target for future therapy. Surg Oncol. 2002 Jun; 11 (1 - 2) : 85 - 100.
5. Weidner N. Intratumoral vascularity as a prognostic factor in cancers of the urogenital tract. Eur J Cancer. 1996 Dec; 32A (14): 2506 - 12.
6. Sobin HW, C Urogenital tumors, in TNM Classification of Malignant Tumors. 5th ed. ed. New York: John Wiley & Sons 1997.
7. Mostofi FK Sobin LH, Torloni H. Histologic typing of urinary bladder tumors , International Histological Classification of Tumors; World Health Organization: Geneva 1973 .
8. Barth PJ, Weingartner K, Kohler HH, Bittinger A. Assessment of the vascularization in prostatic carcinoma: a morphometric investigation. Hum Pathol. 1996 Dec; 27 (12): 1306 - 10.
9. Jones A, Fujiyama C. Angiogenesis in urological malignancy: prognostic indicator and therapeutic target. BJU Int. 1999 Mar ; 83 (5) : 535 - 55 ; quiz 55 - 6.
10. Campbell SC. Advances in angiogenesis research: relevance to urological oncology. J Urol. 1997 Nov;158(5):1663-74.
11. Reiher F, Ozer O, Pins M, et al. p53 and microvessel density in primary resection specimens of superficial bladder cancer. J Urol. 2002 Mar ; 167 (3) : 1469 - 74.
12. Chaudhary R, Bromley M, Clarke NW, et al. Prognostic relevance of micro-vessel density in cancer of the urinary bladder. Anticancer Res. 1999 Jul - Aug ; 19 (4C) : 3479 - 84.
13. Dickinson AJ, Fox SB, Persad RA, et al. Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas. Br J Urol. 1994 Dec ; 74 (6) : 762 - 6.
14. Dinney CP, Babkowski RC, Antelo M, et al. Relationship among cystectomy, microvessel density and prognosis in stage T1 urothelial carcinoma of the bladder. J Urol. 1998 Oct ; 160 (4) : 1285 - 90.
15. MacLennan GT, Bostwick DG. Microvessel density in renal cell carcinoma: lack of prognostic significance. Urology. 1995 Jul ; 46 (1) : 27 - 30.
16. Rubin MA, Buyyounouski M, Bagiella E, et al. Microvessel density in prostate cancer: lack of correlation with tumor grade, pathologic stage, and clinical outcome. Urology. 1999 Mar ; 53 (3) : 542 - 7.
17. Delahunt B, Bethwaite PB, Thornton A. Prognostic significance of microscopic vascularity for clear cell renal cell carcinoma. Br J Urol. 1997 Sep;80 (3): 401 - 4.
18. Kohler HH, Barth PJ, Siebel A, et al. Quantitative assessment of vascular surface density in renal cell carcinomas. Br J Urol. 1996 May ; 77 (5) :650 - 4.
19. Sagol O, Yorukoglu K, Sis B, et al. Does angiogenesis predict recurrence in superficial urothelial carcinoma of the bladder? Urology. 2001 May ; 57 (5) :895 - 9.
20. Santos L, Costa C, Pereira S, et al. Neovascularisation is a prognostic factor of early recurrence in T1/G2 urothelial bladder tumours. Ann Oncol. 2003 Sep;14 (9) :1419 - 24.
21. Goddard JC, Sutton CD, Berry DP, et al. The use of microvessel density in assessing human urological tumours. BJU Int. 2001 Jun ; 87 (9) : 866 - 75.
22. Goddard JC, Sutton CD, Furness PN, et al. Microvessel density at presentation predicts subsequent muscle invasion in superficial bladder cancer. Clin Cancer Res. 2003 Jul ; 9 (7) : 2583 - 6.
23. Ozer E, Yorukoglu K, Kirkali Z. Tumor angiogenesis in superficial bladder cancer. Urol Integr Invest. 2001 ; 6 (1) : 70 - 8.